Our Company

Company Summary

Iterum Therapeutics plc: Headquartered in Dublin, Ireland, we are dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. In October 2024, the US Food and Drug Administration (FDA) approved ORLYNVAH^TM, the first and only approved oral penem, for the treatment of uncomplicated urinary tract infections (uUTI) in patients who have limited or no alternative oral antibiotic treatments.

The Company is led by industry veteran Corey Fishman.

Mr. Fishman has over 30 years of pharmaceutical experience including negotiating and successfully selling two pharma companies for ~$1.5B, leading a wide variety of functions and raising over $600M of capital to-date (including two successful IPOs – one of which was for Iterum Therapeutics plc).

Prior to founding Iterum Therapeutics, Mr. Fishman served as Chief Financial Officer and Chief Operating Officer of Durata Therapeutics. Inc. where he oversaw all aspects of finance and administration, strategy, manufacturing, business development, international operations and portfolio optimization. While at Durata, he raised over $225M in capital, including a successful IPO and secondary public offering as well as led the negotiation and sale of the company to Actavis plc in 2014. Previously, Mr. Fishman served as CFO of MedPointe Healthcare, Inc., a private equity backed specialty pharmaceutical company, where he was responsible for finance, strategy, business development, portfolio optimization and manufacturing; he ultimately led the negotiation and sale of the company to Meda AB.

1. http://www.cdc.gov/drugresistance/biggest_threats.html
2. http://www.cdc.gov/drugresistance/about.html
3. http://www.cdc.gov/drugresistance/threat-report-2013/
4. http://www.antibioticsnow.org/policysplash/